Pharmacological Treatment and Monitoring of Osteoporosis

Pharmacological Treatment and Monitoring of Osteoporosis

 

The selection of medications for osteoporosis should consider the mechanism of action, effectiveness in increasing bone density, fracture risk reduction, contraindications, and potential side effects. Treatment should be individualized (tailored therapy).

 

Goals of Treatment

 

๐​ Reduce the risk of fractures

๐ Slow or prevent bone loss

๐​ Relieve pain from fractures

๐ Reduce disability

๐ Improve quality of life

 

Indications for Treatment

 

Postmenopausal women and men aged ≥ 50 years at high fracture risk should receive medication if any of the following are present:

๐ History of vertebral or hip fracture

๐ T-score ≤ -2.5 at the spine or hip

๐ T-score between -1.0 and -2.5 with a 10-year hip fracture risk ≥3% (using FRAX for Thailand)

๐​ T-score between -1.0 and -2.5 with other fragility fractures (e.g., humerus, pelvis, wrist)

 

Types of Osteoporosis Medications

 

1. Antiresorptive Agents

 

These drugs primarily inhibit bone resorption, including:

๐ Estrogen

๐ SERMs

๐ Bisphosphonates

๐​ Denosumab

 

2. Bone-Forming Agents

 

These stimulate bone formation (anabolic effect), including:

๐ Teriparatide

๐ Abaloparatide

 

3. Dual-Action Agents

 

These have both antiresorptive and bone-forming effects:

๐ Calcium, vitamin D analogs, vitamin K2 (mainly antiresorptive)

๐ Romosozumab (a newer “decoupling agent” that both increases formation and decreases resorption)

 

 

Combined Approach

 

Drug therapy should always be combined with non-pharmacological management, such as:

๐ Lifestyle modification

๐ Adequate calcium, vitamin D, and protein intake

๐ Regular exercise

๐ Fall prevention

 

Prevention of Osteoporosis

 

๐ Ensure adequate calcium and vitamin D intake

๐ Exercise regularly (weight-bearing and muscle-strengthening activities)

๐ Maintain healthy body weight (BMI 20-23 kg/m²)

๐ ​Avoid smoking and excessive alcohol or caffeine

๐ Manage underlying conditions causing secondary osteoporosis

 

Monitoring Treatment

๐ Bone Mineral Density (BMD) measurement using DXA (hip and spine) every 1-2 years

๐ Bone turnover markers (blood tests) at 3-6 months after starting treatment to assess response and adherence

 

Conclusion

 

Effective osteoporosis management requires individualized drug therapy combined with lifestyle changes and regular monitoring to optimize bone health and reduce fracture risk.

 

 

 

 

source : Dr. Tanawat Amphansap

**Translated and compiled by ArokaGO Content Team